May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
Phase I Clinical Trial on Intraocular Pressure-Lowering Effects and Safety of Topical Administration of a Selective ROCK Inhibitor, SNJ-1656, in Normal Volunteers
Author Affiliations & Notes
  • H. Tanihara
    Department of Ophthalmology & Visual Science, Kumamoto University Graduate School of Medicine, Kumamoto, Japan
  • M. Inatani
    Department of Ophthalmology & Visual Science, Kumamoto University Graduate School of Medicine, Kumamoto, Japan
  • M. Honjo
    Department of Ophthalmology & Visual Science, Kyoto University Graduate School of Medicine, Kyoto, Japan
  • H. Toskushige
    Senju Pharmaceutical Com., Ltd., Osaka, Japan
  • J.-I. Azuma
    Clinical Evaluation of Medicine and Therapeutics, Graduate School of Pharmaceutical Sciences and Medicine, Osaka University, Osaka, Japan
  • M. Araie
    Department of Ophthalmology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
  • Footnotes
    Commercial Relationships H. Tanihara, Senju Pharmaceutical Com., Ltd., C; M. Inatani, None; M. Honjo, None; H. Toskushige, Senju Pharmaceutical Com., Ltd., E; J. Azuma, Senju Pharmaceutical Com., Ltd., C; M. Araie, Senju Pharmaceutical Com., Ltd., C.
  • Footnotes
    Support None.
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 5573. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      H. Tanihara, M. Inatani, M. Honjo, H. Toskushige, J.-I. Azuma, M. Araie; Phase I Clinical Trial on Intraocular Pressure-Lowering Effects and Safety of Topical Administration of a Selective ROCK Inhibitor, SNJ-1656, in Normal Volunteers. Invest. Ophthalmol. Vis. Sci. 2007;48(13):5573.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose:: To investigate the effects and safety of topical administration of 0.003 to 0.1% SNJ-1656 in healthy male adult volunteers.

Methods:: Randomized, double-masked, group-comparison, phase I clinical study. In the initial single-dose trial, 45 normal healthy volunteers were randomly subdivided into five groups, which were treated with 0.003%, 0.01%, 0.03%, 0.05%, and 0.1% SNJ-1656 ophthalmic solution (n= 6 in SNJ-1656 and n=3 in placebo in each group) in stepwise fashion. IOP was measured by non-contact tonometry before and at 1, 2, 4, 8, 12, and 24 hours after instillation. In the repeated-instillation trial, 36 normal healthy volunteers were assigned to four groups: 0.05% SNJ-1656 once daily, 0.1% once daily, 0.05% twice daily, or 0.1% twice daily.

Results:: Following single instillation of placebo, 0.003%, 0.01%, 0.03%, 0.05% and 0.1% SNJ-1656, IOP reduction from the baseline was -0.91, - 1.18, - 1.48, - 2.20 (p<0.05 vs placebo), - 1.48 and - 1.98 mmHg at 2 hours, and - 0.63, - 0.95, - 1.79, - 2.26 (p<0.01), - 1.95 and - 3.0 (p<0.01) mmHg at 4 hours, respectively. Following repeated instillation of placebo, 0.05% and 0.1% SNJ-1656 once daily, IOP reductions from the baseline on the 7th day were -1.86, -2.78 and -3.70 (p<0.01) mmHg at 2 hours, and - 1.58, - 1.87 and -4.12 (p<0.01) mmHg at 4 hours, respectively. Following repeated instillation of placebo, 0.05% and 0.1% SNJ-1656 twice daily, IOP reductions on the 7th day were - 0.92, - 3.45 (p<0.01) and -2.51 (p<0.05) mmHg at 2 hours, and - 1.19, - 2.87 (p<0.05) and -2.94 (p<0.01) mmHg at 4 hours, respectively. On slit-lamp examination during the trial, there were no significant adverse findings except injection of the bulbar and palpebral conjunctiva following instillation. In addition, no abnormalities were found in blood pressure, pulse, body temperature, or the electrocardiogram.

Conclusions:: This clinical study demonstrated that SNJ-1656 ophthalmic solution is a safe topical agent effective in reducing IOP in eyes of healthy volunteers with both single and 7-day administrations, with only topical side effects.

Clinical Trial:: Phase I pharmaceutical trial

Keywords: intraocular pressure • drug toxicity/drug effects • conjunctiva 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×